| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | ||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 11/10/2026 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
|||||||||||||||||||||||||
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 11/10/2026 | A | 250,000(1) | A | $0(1) | 250,000 | D | |||
| Common Stock | 20,000 | I | By Lara Knuettel Revocable Trust(2) | |||||||
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock options (right to buy) | $0.89 | 11/10/2026 | A | 750,000 | (3) | 11/10/2036 | Common Stock | 750,000 | $0 | 750,000 | D | ||||
| Explanation of Responses: |
| 1. On November 10, 2026 (the "Grant Date"), the reporting person was granted 250,000 restricted stock units ("RSUs") pursuant to the terms and conditions of a restricted stock unit award agreement and the issuer's amended and restated 2023 incentive compensation plan. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting and settlement. 20% of the RSUs vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date. |
| 2. The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 3. On the Grant Date, the reporting person was granted options to purchase 750,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. 20% of these options vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date. |
| /s/ Francis Knuettel II | 11/12/2026 | |
| ** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.